International Journal of
Reproductive Biomedicine
Sun, Sep 6, 2026
[Archive]
Volume 24, Issue 7 (July 2026)
IJRM 2026, 24(7): 605-616 |
Back to browse issues page
Ethics code: CTRI/2024/02/063174
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Kriplani A, Taneja A, Shankar Kamilya G, Ramani Devi T, Pawar A, Gupta T, et al . Oral dydrogesterone versus oral micronized progesterone: Interim analysis of a randomized controlled trial in pregnant women with threatened miscarriage. IJRM 2026; 24 (7) :605-616
URL: http://ijrm.ir/article-1-3775-en.html
URL: http://ijrm.ir/article-1-3775-en.html
Alka Kriplani1 
, Ashima Taneja2 , Gouri Shankar Kamilya3 , Thirunavukkarasu Ramani Devi4 , Amol Pawar5 , Tanusree Gupta6 , Gayathri Karthik Nagesh7 , Shilpa Choudhary8 , Tapan Pattanaik9 , Monjori Mitra *10
, Ashima Taneja2 , Gouri Shankar Kamilya3 , Thirunavukkarasu Ramani Devi4 , Amol Pawar5 , Tanusree Gupta6 , Gayathri Karthik Nagesh7 , Shilpa Choudhary8 , Tapan Pattanaik9 , Monjori Mitra *10
1- Department of Obstetrics and Gynecology, Paras Hospitals, Gurugram, Haryana, India.
2- Department of Obstetrics and Gynecology, Dayanand Medical College & Hospital, Ludhiana, Punjab, India.
3- Department of Obstetrics and Gynecology, IPGME&R and SSKM Hospital, Kolkata, West Bengal, India.
4- Department of Obstetrics and Gynecology, Ramakrishna Medical Center LLP, Tiruchirappalli, Tamil Nadu, India.
5- Department of Obstetrics and Gynecology, Nowrosjee Wadia Maternity Hospital, Mumbai, Maharashtra, India.
6- Department of Gynecology and Obstetrics, Udyan Health Care Pvt. Ltd., Lucknow, Uttar Pradesh, India.
7- Department of Obstetrics and Gynecology, Manipal Hospital, Bengaluru, Karnataka, India.
8- Lifeline Medicare Hospital, Mumbai, Maharashtra, India.
9- Department of Obstetrics and Gynecology, Sum Ultimate Medicare Hospital, Bhubaneswar, Odisha, India.
10- Department of Pediatrics, Institute of Child Health, Kolkata, West Bengal, India. ,monjorimr@gmail.com
2- Department of Obstetrics and Gynecology, Dayanand Medical College & Hospital, Ludhiana, Punjab, India.
3- Department of Obstetrics and Gynecology, IPGME&R and SSKM Hospital, Kolkata, West Bengal, India.
4- Department of Obstetrics and Gynecology, Ramakrishna Medical Center LLP, Tiruchirappalli, Tamil Nadu, India.
5- Department of Obstetrics and Gynecology, Nowrosjee Wadia Maternity Hospital, Mumbai, Maharashtra, India.
6- Department of Gynecology and Obstetrics, Udyan Health Care Pvt. Ltd., Lucknow, Uttar Pradesh, India.
7- Department of Obstetrics and Gynecology, Manipal Hospital, Bengaluru, Karnataka, India.
8- Lifeline Medicare Hospital, Mumbai, Maharashtra, India.
9- Department of Obstetrics and Gynecology, Sum Ultimate Medicare Hospital, Bhubaneswar, Odisha, India.
10- Department of Pediatrics, Institute of Child Health, Kolkata, West Bengal, India. ,
Abstract: (23 Views)
Background: Progestogen/progestin supplementation is favorable in threatened miscarriage. However, comparative data on the efficacy, safety, and immunomodulatory functions of types/routes of administration are limited.
Objective: This study compares oral dydrogesterone (DYD) vs. oral micronized progesterone (MP) in threatened miscarriage.
Materials and Methods: This ongoing, investigator-initiated, randomized controlled trial includes eligible, consenting, pregnant women who had vaginal bleeding and/or abdominal pain during first trimester. Participants are treated up to 14 gestational wk with DYD (40 mg stat followed by 10 mg thrice daily) or MP (200 mg twice daily). The following outcomes till 20 gestational wk are presented: miscarriage rate (primary); change in serum cytokines (interferon gamma [IFN-γ], tumor necrosis factor alpha [TNF-α], interleukin [IL]-4, IL-10), time to symptom resolution (secondary); treatment-emergent adverse events (AEs; safety).
Results: Interim analysis includes 116 participants (DYD, 62; MP, 54). Miscarriage rate in DYD (14.52%) was statistically comparable to, but numerically lower than, that in MP (20.37%; p = 0.558). The mean time to symptom resolution in DYD and MP was, respectively, 6.49 and 7.38 days for vaginal bleeding, and 7.15 and 7.67 days for abdominal pain. Numerically, IFN-γ and TNF-α decreased and IL-4 increased with DYD, while IFN-γ decreased and IL-4 and IL-10 increased with MP. Considering Th1:Th2 ratio, numerical decreases in IFN-γ:IL-4, IFN-γ:IL-10, and TNF-α:IL-4 were evident with DYD but not with MP. No AE was related to study medication.
Conclusion: Compared to oral MP, oral DYD resulted in a numerically lower miscarriage rate and time to symptom resolution, concomitant to favorable decrease in Th1:Th2 ratio.
Objective: This study compares oral dydrogesterone (DYD) vs. oral micronized progesterone (MP) in threatened miscarriage.
Materials and Methods: This ongoing, investigator-initiated, randomized controlled trial includes eligible, consenting, pregnant women who had vaginal bleeding and/or abdominal pain during first trimester. Participants are treated up to 14 gestational wk with DYD (40 mg stat followed by 10 mg thrice daily) or MP (200 mg twice daily). The following outcomes till 20 gestational wk are presented: miscarriage rate (primary); change in serum cytokines (interferon gamma [IFN-γ], tumor necrosis factor alpha [TNF-α], interleukin [IL]-4, IL-10), time to symptom resolution (secondary); treatment-emergent adverse events (AEs; safety).
Results: Interim analysis includes 116 participants (DYD, 62; MP, 54). Miscarriage rate in DYD (14.52%) was statistically comparable to, but numerically lower than, that in MP (20.37%; p = 0.558). The mean time to symptom resolution in DYD and MP was, respectively, 6.49 and 7.38 days for vaginal bleeding, and 7.15 and 7.67 days for abdominal pain. Numerically, IFN-γ and TNF-α decreased and IL-4 increased with DYD, while IFN-γ decreased and IL-4 and IL-10 increased with MP. Considering Th1:Th2 ratio, numerical decreases in IFN-γ:IL-4, IFN-γ:IL-10, and TNF-α:IL-4 were evident with DYD but not with MP. No AE was related to study medication.
Conclusion: Compared to oral MP, oral DYD resulted in a numerically lower miscarriage rate and time to symptom resolution, concomitant to favorable decrease in Th1:Th2 ratio.
Keywords: Threatened miscarriage, Dydrogesterone, Progesterone, Pregnancy complications, Randomized controlled trial.
Type of Study: Original Article |
Subject:
Reproductive Biology
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
